Back to top
more

Aadi Bioscience (AADI)

(Delayed Data from NSDQ)

$1.75 USD

1.75
147,778

+0.07 (4.17%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.75 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?

Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?

Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 10.45% and 2.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 10.81% and 91.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 20.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Aadi Bioscience, Inc. (AADI)? Wall Street Analysts Think 509.98%

The mean of analysts' price targets for Aadi Bioscience, Inc. (AADI) points to a 510% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -4.69% and 0.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 1.72% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 5.56% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Brookdale Senior Living (BKD) Reports Q4 Loss, Tops Revenue Estimates

Brookdale (BKD) delivered earnings and revenue surprises of 69.77% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?

Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 9.33% and 18.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Misses Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -132.20% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: Preferred Apartment Communities, GCM Grosvenor, Aadi Bioscience and Vivint Smart Home

Zacks.com featured highlights include: Preferred Apartment Communities, GCM Grosvenor, Aadi Bioscience and Vivint Smart Home

Shrabana Mukherjee headshot

4 Stocks to Reap Solid Returns as Analysts Initiate Coverage

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like Preferred Apartment (APTS), GCM (GCMG), Aadi (AADI) & Vivint (VVNT).